A Phase 3 interventional study of Investigational medical product (IMP) administered in parent study in Osteoarthritis, Cancer Pain and Recurrent Low Back Pain, sponsored by Pfizer. Completed at 6 sites in United States. Open to participants aged 0 Years to 2 Months. Per ClinicalTrials.gov, last updated 2021-06-25.
Sponsored by Pfizer · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Osteoarthritis by Pfizer — 2 open to participants now, 2 under way, 2 of them phase 3. Osteoarthritis · Pfizer.
Among the 39 studies in Osteoarthritis by Pfizer, this one is the 34th largest by enrollment of the 37 interventional ones that give a count, is the only one that started in 2017, is one of 21 in phase 3, and was the 37th registered.
2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →2 of the 39 studies in Osteoarthritis by Pfizer are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 0 Years to 2 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 80 across 2,241 interventional studies indexed under Osteoarthritis.
Median enrollment 265 across the 37 interventional studies. Of the 36 that completed or were terminated, 20 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 39 studies in Osteoarthritis by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A4091065 is a multicenter, prospective, cohort study with enhance physical an neurodevelopmental surveillance to characterize the outcomes related to the development of infants up to the age of 15 months who were potentially exposed to tanezumab, placebo or comparator via maternal exposure or in utero in any tanezumb study.
A4091065 is a long term observational follow up study of subjects from tanezumab interventional studies A4091056, A4091057, A4091058, A4091059, A4091061 or A4091063
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Long term observational study of subjects from tanezumab parent study
Drug: Investigational medical product (IMP) administered in parent study
IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study
Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Occipital-frontal head circumference of participants in centimeter (cm) was reported.
Time frame: Any visit during participants' age from 0 to 2 Months
Occipital-frontal Head Circumference at 8 Months of Participant's Age
Occipital-frontal head circumference of participants in centimeter (cm) was reported.
Time frame: At 8 Months of participants' age
Occipital-frontal Head Circumference at 15 Months of Participant's Age
Occipital-frontal head circumference of participants in centimeter (cm) was reported.
Time frame: At 15 Months of participants' age
Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 3 Months of Participant's Age
Occipital-frontal head circumference of participants in centimeter (cm) was reported.
Time frame: Any visit during participants' age from 0 to 3 Months
Occipital-frontal Head Circumference During Greater Than (>) 3 to <=6 Months of Participant's Age
Occipital-frontal head circumference of participants in cm was reported.
Time frame: Any visit during participants' age above 3 Months and up to 6 Months
Occipital-frontal Head Circumference During >6 to <=9 Months of Participant's Age
Occipital-frontal head circumference of participants in cm was reported.
Time frame: Any visit during participants' age above 6 Months and up to 9 Months
Occipital-frontal Head Circumference During >15 to <=18 Months of Participant's Age
Occipital-frontal head circumference of participants in cm was reported.
Time frame: Any visit during participants' age above 15 Months and up to 18 Months
Occipital-frontal Head Circumference During >21 to <=24 Months of Participant's Age
Occipital-frontal head circumference of participants in cm was reported.
Time frame: Any visit during participants' age above 21 Months and up to 24 Months
Occipital-frontal Head Circumference During >24 to <=30 Months of Participant's Age
Occipital-frontal head circumference of participants in cm was reported.
Time frame: Any visit during participants' age above 24 Months and up to 30 Months
Body Length During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Body length of participants in cm was reported.
Time frame: Any visit during participants' age from 0 to 2 Months
Body Length at 8 Months of Participant's Age
Body length of participants in cm was reported.
Time frame: At 8 Months of participant's age
Body Length at 15 Months of Participant's Age
Body length of participants in cm was reported.
Time frame: At 15 Months of participant's age
Body Length During 0 to <=3 Months of Participant's Age
Body length of participants in cm was reported.
Time frame: Any visit during participants' age from 0 to 3 Months
Body Length During >3 to <=6 Months of Participant's Age
Body length of participants in cm was reported.
Time frame: Any visit during participants' age above 3 Months and up to 6 Months
Body Length During >6 to <=9 Months of Participant's Age
Body length of participants in cm was reported.
Time frame: Any visit during participants' age above 6 Months and up to 9 Months
Body Length During >15 to <=18 Months of Participant's Age
Body length of participants in cm was reported.
Time frame: Any visit during participants' age above 15 Months and up to 18 Months
Body Length During >21 to <=24 Months of Participant's Age
Body length of participants in cm was reported.
Time frame: Any visit during participants' age above 21 Months and up to 24 Months
Body Length During >24 to <=30 Months of Participant's Age
Body length of participants in cm was reported.
Time frame: Any visit during participants' age above 24 Months and up to 30 Months
Body Weight During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Body weight of participants in kilogram (kg) was reported.
Time frame: Any visit during participants' age from 0 to 2 Months
Body Weight at 8 Months of Participant's Age
Body weight of participants in kilogram (kg) was reported.
Time frame: At 8 Months of participants' age
Body Weight at 15 Months of Participant's Age
Body weight of participants in kilogram (kg) was reported.
Time frame: At 15 Months of participants' age
Body Weight During 0 to <=3 Months of Participant's Age
Body weight of participants in kilogram (kg) was reported.
Time frame: Any visit during participants' age from 0 to 3 Months
Body Weight During >3 to <=6 Months of Participant's Age
Body weight of participants in kg was reported.
Time frame: Any visit during participants' age above 3 Months and up to 6 Months
Body Weight During >6 to <=9 Months of Participant's Age
Body weight of participants in kg was reported.
Time frame: Any visit during participants' age above 6 Months and up to 9 Months
Body Weight During >15 to <=18 Months of Participant's Age
Body weight of participants in kg was reported.
Time frame: Any visit during participants' age above 15 Months and up to 18 Months
Body Weight During >21 to <=24 Months of Participant's Age
Body weight of participants in kg was reported.
Time frame: Any visit during participants' age above 21 Months and up to 24 Months
Body Weight During >24 to <=30 Months of Participant's Age
Body weight of participants in kg was reported.
Time frame: Any visit during participants' age above 24 Months up to 30 Months
Systolic and Diastolic Blood Pressure During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.
Time frame: Any visit during participants' age from 0 to 2 Months
Systolic and Diastolic Blood Pressure at 8 Months of Participant's Age
Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.
Time frame: At 8 Months of participants' age
Systolic and Diastolic Blood Pressure at 15 Months of Participant's Age
Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.
Time frame: At 15 Months participants' age
Systolic and Diastolic Blood Pressure During 0 to <=3 Months of Participant's Age
Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.
Time frame: Any visit during participants' age from 0 to 3 Months
Systolic and Diastolic Blood Pressure During >3 to <=6 Months of Participant's Age
Systolic and diastolic blood pressure of participants in mmHg was reported.
Time frame: Any visit during participants' age above 3 Months and up to 6 Months
Systolic and Diastolic Blood Pressure During >6 to <=9 Months of Participant's Age
Systolic and diastolic blood pressure of participants in mmHg was reported.
Time frame: Any visit during participants' age above 6 Months and up to 9 Months
Systolic and Diastolic Blood Pressure During >15 to <=18 Months of Participant's Age
Systolic and diastolic blood pressure of participants in mmHg was reported.
Time frame: Any visit during participants' age above 15 Months and up to 18 Months
Systolic and Diastolic Blood Pressure During >21 to <=24 Months of Participant's Age
Systolic and diastolic blood pressure of participants in mmHg was reported.
Time frame: Any visit during participants' age above 21 Months and up to 24 Months
Systolic and Diastolic Blood Pressure During >24 to <=30 Months of Participant's Age
Systolic and diastolic blood pressure of participants in mmHg was reported.
Time frame: Any visit during participants' age above 24 Months and up to 30 Months
Pulse Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Pulse rate of participants in beats per minute was reported.
Time frame: Any visit during participants' age from 0 to 2 Months
Pulse Rate at 8 Months of Participant's Age
Pulse rate of participants in beats per minute was reported.
Time frame: At 8 Months of participants' age
Pulse Rate at 15 Months of Participant's Age
Pulse rate of participants in beats per minute was reported.
Time frame: At 15 Months of participants' age
Pulse Rate During 0 to <=3 Months of Participant's Age
Pulse rate of participants in beats per minute was reported.
Time frame: Any visit during participants' age from 0 to 3 Months
Pulse Rate During >3 to <=6 Months of Participant's Age
Pulse rate of participants in beats per minute was reported.
Time frame: Any visit during participants' age above 3 Months and up to 6 Months
Pulse Rate During >6 to <=9 Months of Participant's Age
Pulse rate of participants in beats per minute was reported.
Time frame: Any visit during participants' age above 6 Months and up to 9 Months
Pulse Rate During >15 to <=18 Months of Participant's Age
Pulse rate of participants in beats per minute was reported.
Time frame: Any visit during participants' age above 15 Months and up to 18 Months
Pulse Rate During >21 to <=24 Months of Participant's Age
Pulse rate of participants in beats per minute was reported.
Time frame: Any visit during participants' age above 21 Months and up to 24 Months
Pulse Rate During >24 to <=30 Months of Participant's Age
Pulse rate of participants in beats per minute was reported.
Time frame: Any visit during participants' age above 24 Months and up to 30 Months
Temperature During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Temperature of participants in degree Celsius was reported.
Time frame: Any visit during participants' age from 0 to 2 Months
Temperature at 8 Months of Participant's Age
Temperature of participants in degree Celsius was reported.
Time frame: At 8 Months of participants' age
Temperature at 15 Months of Participant's Age
Temperature of participants in degree Celsius was reported.
Time frame: At 15 Months of participants' age
Temperature During 0 to <=3 Months of Participant's Age
Temperature of participants in degree Celsius was reported.
Time frame: Any visit during participants' age from 0 to 3 Months
Temperature During >3 to <=6 Months of Participant's Age
Temperature of participants in degree Celsius was reported.
Time frame: Any visit during participants' age above 3 Months and up to 6 Months
Temperature During >6 to <=9 Months of Participant's Age
Temperature of participants in degree Celsius was reported.
Time frame: Any visit during participants' age above 6 Months and up to 9 Months
Temperature During >15 to <=18 Months of Participant's Age
Temperature of participants in degree Celsius was reported.
Time frame: Any visit during participants' age above 15 Months and up to 18 Months
Temperature During >21 to <=24 Months of Participant's Age
Temperature of participants in degree Celsius was reported.
Time frame: Any visit during participants' age above 21 Months and up to 24 Months
Temperature During >24 to <=30 Months of Participant's Age
Temperature of participants in degree Celsius was reported.
Time frame: Any visit during participants' age above 24 Months and up to 30 Months
Respiratory Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Respiratory rate of participants in breaths per minute was reported.
Time frame: Any visit during participants' age from 0 to 2 Months
Respiratory Rate at 8 Months of Participant's Age
Respiratory rate of participants in breaths per minute was reported.
Time frame: At 8 Months of participants' age
Respiratory Rate at 15 Months of Participant's Age
Respiratory rate of participants in breaths per minute was reported.
Time frame: At 15 Months participants' age
Respiratory Rate During 0 to <=3 Months of Participant's Age
Respiratory rate of participants in breaths per minute was reported.
Time frame: Any visit during participants' age from 0 to 3 Months
Respiratory Rate During >3 to <=6 Months of Participant's Age
Respiratory rate of participants in breaths per minute was reported.
Time frame: Any visit during participants' age above 3 Months and up to 6 Months
Respiratory Rate During >6 to <=9 Months of Participant's Age
Respiratory rate of participants in breaths per minute was reported.
Time frame: Any visit during participants' age above 6 Months and up to 9 Months
Respiratory Rate During >15 to <=18 Months of Participant's Age
Respiratory rate of participants in breaths per minute was reported.
Time frame: Any visit during participants' age above 15 Months and up to 18 Months
Respiratory Rate During >21 to <=24 Months of Participant's Age
Respiratory rate of participants in breaths per minute was reported.
Time frame: Any visit during participants' age above 21 Months and up to 24 Months
Respiratory Rate During >24 to <=30 Months of Participant's Age
Respiratory rate of participants in breaths per minute was reported.
Time frame: Any visit during participants' age above 24 Months and up to 30 Months
Number of Participants With Abnormal Neurological Examination Findings During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.
Time frame: Any visit during participants' age from 0 to 2 Months
Number of Participants With Abnormal Neurological Examination Findings at 8 Months of Participant's Age
Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.
Time frame: At 8 Months of participants' age
Number of Participants With Abnormal Neurological Examination Findings at 15 Months of Participant's Age
Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.
Time frame: At 15 Months of participants' age
Number of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 1 (Month 20 of Participant's Age)
Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.
Time frame: Follow-up Visit 1 (At the age of Month 20)
Number of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 2 (Month 26 of Participant's Age)
Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.
Time frame: Follow-up Visit 2 (At the age of 26 Months)
Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 8 of Participant's Age
BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.
Time frame: At 8 Months of participants' age
Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 15 of Participant's Age
BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.
Time frame: At 15 Months of participants' age
Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 1 (Month 20 of Participant's Age)
BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.
Time frame: Follow-up Visit 1 (At the age of Month 20)
Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 2 (Month 26 of Participant's Age)
BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance. Data collected at age of 26 months used 24 months' age items.
Time frame: Follow-up Visit 2 (At the age of Month 26)
Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 8 of Participant's Age
REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.
Time frame: At 8 Months of participants' age
Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 15 of Participant's Age
REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.
Time frame: At 15 Months of participants' age
Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 1 (Month 20 of Participant's Age)
REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.
Time frame: Follow-up Visit 1 (At the age of Month 20)
Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 2 (Month 26 of Participant's Age)
REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.
Time frame: Follow-up Visit 2 (At the age of Month 26)
Infants to be enrolled were exposed potentially to tanezumab, placebo or comparator via maternal exposure at conception or in-utero during tanezumab clinical program, in any of the following studies: A4091056 (NCT02697773), A4091057 (NCT02709486), A4091058 (NCT02528188), A4091059 (NCT02528253), A4091061 (NCT02609828) or A4091063 (NCT02725411). Total 4 eligible infants were enrolled. Out of 4, 2 had tanezumab exposure, 2 had comparator (tramadol) exposure and none had placebo exposure.
| Milestone | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Started | 2 | 2 |
| Completed | 1 | 2 |
| Not completed | 1 | 0 |
| Withdrew: Death | 1 | 0 |
Occipital-frontal head circumference of participants in centimeter (cm) was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age | 38.7 | 38.7 ± 1.63 |
Occipital-frontal head circumference of participants in centimeter (cm) was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Occipital-frontal Head Circumference at 8 Months of Participant's Age | 47.0 ± 1.41 | 47.2 ± 1.44 |
Occipital-frontal head circumference of participants in centimeter (cm) was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Occipital-frontal Head Circumference at 15 Months of Participant's Age | 49.2 ± 2.33 | 48.9 ± 2.69 |
Occipital-frontal head circumference of participants in centimeter (cm) was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 3 Months of Participant's Age | 38.7 | 38.7 ± 1.63 |
Occipital-frontal head circumference of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Occipital-frontal Head Circumference During Greater Than (>) 3 to <=6 Months of Participant's Age | 44.0 | — |
Occipital-frontal head circumference of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Occipital-frontal Head Circumference During >6 to <=9 Months of Participant's Age | 47.0 ± 1.41 | 47.2 ± 1.44 |
Occipital-frontal head circumference of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Occipital-frontal Head Circumference During >15 to <=18 Months of Participant's Age | 49.2 ± 2.33 | 48.9 ± 2.69 |
Occipital-frontal head circumference of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Occipital-frontal Head Circumference During >21 to <=24 Months of Participant's Age | 49.0 | — |
Occipital-frontal head circumference of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Occipital-frontal Head Circumference During >24 to <=30 Months of Participant's Age | 50.5 | — |
Body length of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Length During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age | 54.6 | 56.5 ± 1.41 |
Body length of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Length at 8 Months of Participant's Age | 73.6 ± 3.45 | 73.7 ± 1.80 |
Body length of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Length at 15 Months of Participant's Age | 82.3 ± 3.95 | 81.3 ± 0.00 |
Body length of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Length During 0 to <=3 Months of Participant's Age | 54.6 | 56.5 ± 1.41 |
Body length of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Length During >3 to <=6 Months of Participant's Age | 72.4 | — |
Body length of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Length During >6 to <=9 Months of Participant's Age | 73.6 ± 3.45 | 73.7 ± 1.80 |
Body length of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Length During >15 to <=18 Months of Participant's Age | 82.3 ± 3.95 | 81.3 ± 0.00 |
Body length of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Length During >21 to <=24 Months of Participant's Age | 92.5 | — |
Body length of participants in cm was reported.
| cm | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Length During >24 to <=30 Months of Participant's Age | 97.8 | — |
Body weight of participants in kilogram (kg) was reported.
| kg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Weight During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age | 3.4 | 5.8 ± 1.03 |
Body weight of participants in kilogram (kg) was reported.
| kg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Weight at 8 Months of Participant's Age | 11.3 ± 2.50 | 11.6 ± 0.39 |
Body weight of participants in kilogram (kg) was reported.
| kg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Weight at 15 Months of Participant's Age | 13.6 ± 2.53 | 13.1 ± 1.09 |
Body weight of participants in kilogram (kg) was reported.
| kg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Weight During 0 to <=3 Months of Participant's Age | 3.4 | 5.8 ± 1.03 |
Body weight of participants in kg was reported.
| kg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Weight During >3 to <=6 Months of Participant's Age | 11.3 | — |
Body weight of participants in kg was reported.
| kg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Weight During >6 to <=9 Months of Participant's Age | 11.3 ± 2.50 | 11.6 ± 0.39 |
Body weight of participants in kg was reported.
| kg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Weight During >15 to <=18 Months of Participant's Age | 13.6 ± 2.53 | 13.1 ± 1.09 |
Body weight of participants in kg was reported.
| kg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Weight During >21 to <=24 Months of Participant's Age | 16.0 | — |
Body weight of participants in kg was reported.
| kg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Body Weight During >24 to <=30 Months of Participant's Age | 18.4 | — |
Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.
| mmHg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Systolic Blood Pressure | 90.0 | NA ± NA |
| Diastolic Blood Pressure | 60.0 | NA ± NA |
Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.
| mmHg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Systolic Blood Pressure | 95.5 ± 19.09 | 82.0 |
| Diastolic Blood Pressure | 66.0 ± 8.49 | 40.0 |
Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.
| mmHg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Systolic Blood Pressure | 94.5 ± 7.78 | 80.0 ± 2.83 |
| Diastolic Blood Pressure | 58.5 ± 2.12 | 43.0 ± 4.24 |
Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.
| mmHg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Systolic Blood Pressure | 90.0 | NA ± NA |
| Diastolic Blood Pressure | 60.0 | NA ± NA |
Systolic and diastolic blood pressure of participants in mmHg was reported.
No measurements were reported for this outcome.
Systolic and diastolic blood pressure of participants in mmHg was reported.
| mmHg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Systolic Blood Pressure | 95.5 ± 19.09 | 82.0 |
| Diastolic Blood Pressure | 66.0 ± 8.49 | 40.0 |
Systolic and diastolic blood pressure of participants in mmHg was reported.
| mmHg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Systolic Blood Pressure | 94.5 ± 7.78 | 80.0 ± 2.83 |
| Diastolic Blood Pressure | 58.5 ± 2.12 | 43.0 ± 4.24 |
Systolic and diastolic blood pressure of participants in mmHg was reported.
| mmHg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Systolic Blood Pressure | 123.0 | — |
| Diastolic Blood Pressure | 78.0 | — |
Systolic and diastolic blood pressure of participants in mmHg was reported.
| mmHg | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Systolic Blood Pressure | 101.0 | — |
| Diastolic Blood Pressure | 55.0 | — |
Pulse rate of participants in beats per minute was reported.
| beats per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Pulse Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age | 124.0 | 144.0 ± 15.56 |
Pulse rate of participants in beats per minute was reported.
| beats per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Pulse Rate at 8 Months of Participant's Age | 117.0 ± 15.56 | 121.0 ± 4.24 |
Pulse rate of participants in beats per minute was reported.
| beats per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Pulse Rate at 15 Months of Participant's Age | 108.5 ± 20.51 | 116.0 ± 5.66 |
Pulse rate of participants in beats per minute was reported.
| beats per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Pulse Rate During 0 to <=3 Months of Participant's Age | 124.0 | 144.0 ± 15.56 |
Pulse rate of participants in beats per minute was reported.
| beats per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Pulse Rate During >3 to <=6 Months of Participant's Age | 128.0 | — |
Pulse rate of participants in beats per minute was reported.
| beats per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Pulse Rate During >6 to <=9 Months of Participant's Age | 117.0 ± 15.56 | 121.0 ± 4.24 |
Pulse rate of participants in beats per minute was reported.
| beats per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Pulse Rate During >15 to <=18 Months of Participant's Age | 108.5 ± 20.51 | 116.0 ± 5.66 |
Pulse rate of participants in beats per minute was reported.
| beats per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Pulse Rate During >21 to <=24 Months of Participant's Age | 118.0 | — |
Pulse rate of participants in beats per minute was reported.
| beats per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Pulse Rate During >24 to <=30 Months of Participant's Age | 118.0 | — |
Temperature of participants in degree Celsius was reported.
| degree Celsius | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Temperature During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age | 36.2 | 36.6 ± 0.08 |
Temperature of participants in degree Celsius was reported.
| degree Celsius | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Temperature at 8 Months of Participant's Age | 36.3 ± 0.27 | 36.7 ± 0.08 |
Temperature of participants in degree Celsius was reported.
| degree Celsius | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Temperature at 15 Months of Participant's Age | 36.1 ± 0.47 | 36.5 ± 0.04 |
Temperature of participants in degree Celsius was reported.
| degree Celsius | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Temperature During 0 to <=3 Months of Participant's Age | 36.2 | 36.6 ± 0.08 |
Temperature of participants in degree Celsius was reported.
| degree Celsius | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Temperature During >3 to <=6 Months of Participant's Age | 36.4 | — |
Temperature of participants in degree Celsius was reported.
| degree Celsius | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Temperature During >6 to <=9 Months of Participant's Age | 36.3 ± 0.27 | 36.7 ± 0.08 |
Temperature of participants in degree Celsius was reported.
| degree Celsius | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Temperature During >15 to <=18 Months of Participant's Age | 36.1 ± 0.47 | 36.5 ± 0.04 |
Temperature of participants in degree Celsius was reported.
| degree Celsius | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Temperature During >21 to <=24 Months of Participant's Age | 36.4 | — |
Temperature of participants in degree Celsius was reported.
| degree Celsius | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Temperature During >24 to <=30 Months of Participant's Age | 36.3 | — |
Respiratory rate of participants in breaths per minute was reported.
| breaths per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Respiratory Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age | 30.0 | 57.0 ± 9.90 |
Respiratory rate of participants in breaths per minute was reported.
| breaths per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Respiratory Rate at 8 Months of Participant's Age | 33.0 ± 1.41 | 34.0 ± 2.83 |
Respiratory rate of participants in breaths per minute was reported.
| breaths per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Respiratory Rate at 15 Months of Participant's Age | 34.0 ± 14.14 | 27.0 ± 1.41 |
Respiratory rate of participants in breaths per minute was reported.
| breaths per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Respiratory Rate During 0 to <=3 Months of Participant's Age | 30.0 | 57.0 ± 9.90 |
Respiratory rate of participants in breaths per minute was reported.
| breaths per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Respiratory Rate During >3 to <=6 Months of Participant's Age | 44.0 | — |
Respiratory rate of participants in breaths per minute was reported.
| breaths per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Respiratory Rate During >6 to <=9 Months of Participant's Age | 33.0 ± 1.41 | 34.0 ± 2.83 |
Respiratory rate of participants in breaths per minute was reported.
| breaths per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Respiratory Rate During >15 to <=18 Months of Participant's Age | 34.0 ± 14.14 | 27.0 ± 1.41 |
Respiratory rate of participants in breaths per minute was reported.
| breaths per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Respiratory Rate During >21 to <=24 Months of Participant's Age | 44.0 | — |
Respiratory rate of participants in breaths per minute was reported.
| breaths per minute | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Respiratory Rate During >24 to <=30 Months of Participant's Age | 44.0 | — |
Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.
| Participants | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Number of Participants With Abnormal Neurological Examination Findings During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age | 0 | 0 |
Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.
| Participants | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Number of Participants With Abnormal Neurological Examination Findings at 8 Months of Participant's Age | 0 | 0 |
Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.
| Participants | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Number of Participants With Abnormal Neurological Examination Findings at 15 Months of Participant's Age | 1 | 0 |
Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.
| Participants | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Number of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 1 (Month 20 of Participant's Age) | 1 | 0 |
Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.
| Participants | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Number of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 2 (Month 26 of Participant's Age) | 1 | 0 |
BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.
| units on a scale | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 8 of Participant's Age | NA ± NA | NA ± NA |
BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.
| units on a scale | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 15 of Participant's Age | NA ± NA | NA ± NA |
BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.
| units on a scale | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 1 (Month 20 of Participant's Age) | 7 | — |
BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance. Data collected at age of 26 months used 24 months' age items.
| units on a scale | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 2 (Month 26 of Participant's Age) | 6 | — |
REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.
| units on a scale | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 8 of Participant's Age | NA ± NA | NA ± NA |
REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.
| units on a scale | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 15 of Participant's Age | NA ± NA | NA ± NA |
REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.
| units on a scale | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 1 (Month 20 of Participant's Age) | 88 | — |
REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.
| units on a scale | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 2 (Month 26 of Participant's Age) | 92 | — |
Collected over From the participants' age of 0 month to maximum of 36 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maternal Exposure to Tanezumab | 1/2 (50%) | 1/2 (50%) | 1/2 (50%) |
| Maternal Exposure to Tramadol | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| DrowningGeneral disorders | 1/2 | 0/2 |
| Event | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol |
|---|---|---|
| Speech disorder/ Language development delayNervous system disorders | 1/2 | 0/2 |
| Speech disorder developmental / Speech developmental delayNervous system disorders | 1/2 | 0/2 |
Safety population included all participants who were enrolled into the study.
| Age, Customized(Participants) | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol | Total |
|---|---|---|---|
| Pre-term newborn - gestational age < 37 week | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 2 | 2 | 4 |
| Sex: Female, Male(Participants) | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol | Total |
|---|---|---|---|
| Female | 0 | 1 | 1 |
| Male | 2 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 2 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Maternal Exposure to Tanezumab | Maternal Exposure to Tramadol | Total |
|---|---|---|---|
| Race — White | 0 | 2 | 2 |
| Race — Black or African American | 1 | 0 | 1 |
| Race — Other | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Nov 2017 to primary completion in Jun 2020, 31 months.
Results were first posted in Jun 2021, 1 year after primary completion.
Of 60 industry-sponsored phase 3 interventional studies under Osteoarthritis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 31 months is above that.
Counting every sponsor, half of 84 studies reached it within 17 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inosine Monophosphate